PL365746A1 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number: PL365746A1
Authority: PL; Poland
Prior art keywords: bicalutamide; pharmaceutical formulation; formulation; pharmaceutical
Prior art date: 2001-02-27

Application number

PL02365746A

Other languages

English (en)

Inventor

Nicola Bateman

Julie Cahill

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-27

Filing date

2002-02-22

Publication date

2005-01-10

2001-02-27 Priority claimed from GB0104749A external-priority patent/GB2372444A/en

2001-07-19 Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx

2002-02-22 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-01-10 Publication of PL365746A1 publication Critical patent/PL365746A1/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL02365746A 2001-02-27 2002-02-22 Kompozycja farmaceutyczna PL365746A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0104749A GB2372444A (en)	2001-02-27	2001-02-27	A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv)	2001-07-19	2001-07-19	Pharmaceutical formulation

Publications (1)

Publication Number	Publication Date
PL365746A1 true PL365746A1 (pl)	2005-01-10

Family

ID=26245766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02365746A PL365746A1 (pl)	2001-02-27	2002-02-22	Kompozycja farmaceutyczna

Country Status (22)

Country	Link
US (1)	US20040067257A1 (pl)
EP (1)	EP1368001B1 (pl)
JP (2)	JP3548566B2 (pl)
KR (1)	KR20030077042A (pl)
CN (1)	CN1503662A (pl)
AR (1)	AR032912A1 (pl)
AT (1)	ATE307571T1 (pl)
CA (1)	CA2439366A1 (pl)
CZ (1)	CZ20032225A3 (pl)
DE (1)	DE60206889T2 (pl)
EE (1)	EE200300416A (pl)
HU (1)	HUP0302847A3 (pl)
IL (1)	IL157389A0 (pl)
IS (1)	IS6915A (pl)
MX (1)	MXPA03007641A (pl)
NO (1)	NO20033785L (pl)
NZ (1)	NZ527532A (pl)
PL (1)	PL365746A1 (pl)
RU (1)	RU2003128971A (pl)
SK (1)	SK10722003A3 (pl)
UY (1)	UY27186A1 (pl)
WO (1)	WO2002067893A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
TWI355276B (en) *	2003-01-14	2012-01-01	Akira Tsuji	Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) *	2003-05-14	2005-01-13	Arturo Siles Ortega	Bicalutamide compositions
WO2005074991A1 (ja) *	2004-02-09	2005-08-18	Kabushiki Kaisha Sangi	抗腫瘍剤
KR100539706B1 (ko) *	2005-01-25	2005-12-28	지엘팜텍 주식회사	타크로리무스 및 장용성 고분자를 함유하는 고체분산체
US20080161404A1 (en) *	2005-02-23	2008-07-03	Astrazeneca Ab	Bicalutamide for Delivering Increasing Steady State Plasma Levels
US8293274B2 (en) *	2005-04-06	2012-10-23	Kabushiki Kaisha Sangi	Intestinal absorptive anti-tumor agent
US7785629B2 (en) *	2005-06-21	2010-08-31	Helm Ag	Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) *	2006-06-16	2012-10-17	トーアエイヨー株式会社	腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) *	2006-08-17	2008-02-21	Gawande Rahul S	Bicalutamide compositions
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
JP2010533729A (ja)	2007-07-17	2010-10-28	プレキシコン，インコーポレーテッド	キナーゼ調節のための化合物と方法、及びそのための適応
EP2191830A4 (en)	2007-09-21	2011-11-23	Shionogi & Co	SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
JP5204452B2 (ja) *	2007-10-02	2013-06-05	日医工株式会社	ビカルタミド含有製剤
EP2219624A2 (en) *	2007-11-08	2010-08-25	Glaxo Group Limited	Pharmaceutical formulations
PL2414356T3 (pl)	2009-04-03	2016-02-29	Hoffmann La Roche	Kompozycje {3-[5-(4-chlorofenylo)-1H-pirolo[2,3-b]pirydyno-3-karbonylo]-2,4-difluorofenylo}-amidu kwasu propano-1-sulfonowego i ich zastosowania
CN101987086B (zh) *	2009-08-03	2012-07-18	北京化工大学	一种超细比卡鲁胺口服片剂及其制备方法
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
PE20121327A1 (es)	2009-11-06	2012-10-18	Plexxikon Inc	Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
US9259389B2 (en)	2009-12-18	2016-02-16	Endotis Pharma	Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CN102525876B (zh) *	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) *	2010-12-20	2013-11-20	西安力邦医药科技有限责任公司	拉米夫定固体分散体、其制备方法、药物组合物和用途
PT2672967T (pt)	2011-02-07	2018-12-07	Plexxikon Inc	Compostos e métodos de modulação da quinase e suas indicações
AR085279A1 (es)	2011-02-21	2013-09-18	Plexxikon Inc	Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
AU2013315619B2 (en)	2012-09-11	2018-02-08	Astellas Pharma Inc.	Formulations of enzalutamide
CN106573002A (zh) *	2014-08-07	2017-04-19	药品循环有限责任公司	布鲁顿氏酪氨酸激酶抑制剂的新型制剂
MA41107B1 (fr)	2014-12-05	2025-01-31	Aragon Pharmaceuticals, Inc.	Compositions anti-cancéreuses
ES2883187T3 (es)	2014-12-05	2021-12-07	Aragon Pharmaceuticals Inc	Composiciones anticancerosas
CN109674752B (zh) *	2016-12-15	2022-10-11	华领医药技术（上海）有限公司	葡萄糖激酶激活剂的口服制剂及其制备方法
US11185589B2 (en)	2019-04-11	2021-11-30	R.P. Scherer Technologies, Llc	Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
GB2584341B (en) *	2019-05-31	2023-03-01	Gw Res Ltd	Cannabinoid formulations
US11344526B2 (en)	2020-03-20	2022-05-31	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery
JP7665645B2 (ja)	2020-03-20	2025-04-21	ザリージェンツオブザユニバーシティオブカリフォルニア	局所的な薬物送達のための移植可能な薬物送達デバイス
US11173291B2 (en) *	2020-03-20	2021-11-16	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0100172B1 (en) *	1982-07-23	1987-08-12	Imperial Chemical Industries Plc	Amide derivatives
ATE159426T1 (de) *	1991-04-16	1997-11-15	Nippon Shinyaku Co Ltd	Verfahren zur herstellung einer festen dispersion
EP0748220A4 (en) *	1994-01-21	1997-09-10	Sepracor Inc	METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
US20030059471A1 (en) *	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
HUP0303454A3 (en) *	2001-04-02	2005-12-28	Astrazeneca Ab	Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103839D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product

2002
- 2002-02-22 CA CA002439366A patent/CA2439366A1/en not_active Abandoned
- 2002-02-22 IL IL15738902A patent/IL157389A0/xx unknown
- 2002-02-22 DE DE60206889T patent/DE60206889T2/de not_active Expired - Fee Related
- 2002-02-22 JP JP2002567261A patent/JP3548566B2/ja not_active Expired - Fee Related
- 2002-02-22 AT AT02712105T patent/ATE307571T1/de not_active IP Right Cessation
- 2002-02-22 CZ CZ20032225A patent/CZ20032225A3/cs unknown
- 2002-02-22 KR KR10-2003-7011178A patent/KR20030077042A/ko not_active Withdrawn
- 2002-02-22 NZ NZ527532A patent/NZ527532A/xx unknown
- 2002-02-22 CN CNA028087356A patent/CN1503662A/zh active Pending
- 2002-02-22 EE EEP200300416A patent/EE200300416A/xx unknown
- 2002-02-22 US US10/468,276 patent/US20040067257A1/en not_active Abandoned
- 2002-02-22 HU HU0302847A patent/HUP0302847A3/hu unknown
- 2002-02-22 MX MXPA03007641A patent/MXPA03007641A/es unknown
- 2002-02-22 WO PCT/GB2002/000766 patent/WO2002067893A2/en not_active Ceased
- 2002-02-22 PL PL02365746A patent/PL365746A1/pl not_active Application Discontinuation
- 2002-02-22 RU RU2003128971/15A patent/RU2003128971A/ru not_active Application Discontinuation
- 2002-02-22 SK SK1072-2003A patent/SK10722003A3/sk unknown
- 2002-02-22 EP EP02712105A patent/EP1368001B1/en not_active Expired - Lifetime
- 2002-02-26 UY UY27186A patent/UY27186A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100712A patent/AR032912A1/es not_active Application Discontinuation
2003
- 2003-08-15 IS IS6915A patent/IS6915A/is unknown
- 2003-08-26 NO NO20033785A patent/NO20033785L/no not_active Application Discontinuation
2004
- 2004-02-18 JP JP2004041583A patent/JP2004143185A/ja active Pending

Also Published As

Publication number	Publication date
UY27186A1 (es)	2002-09-30
NO20033785D0 (no)	2003-08-26
JP3548566B2 (ja)	2004-07-28
DE60206889D1 (de)	2005-12-01
KR20030077042A (ko)	2003-09-29
IS6915A (is)	2003-08-15
CZ20032225A3 (cs)	2003-11-12
HUP0302847A3 (en)	2005-05-30
JP2004521918A (ja)	2004-07-22
RU2003128971A (ru)	2005-03-10
IL157389A0 (en)	2004-05-12
EE200300416A (et)	2003-12-15
MXPA03007641A (es)	2003-12-04
WO2002067893A2 (en)	2002-09-06
NO20033785L (no)	2003-10-24
SK10722003A3 (sk)	2004-02-03
AR032912A1 (es)	2003-12-03
EP1368001A2 (en)	2003-12-10
US20040067257A1 (en)	2004-04-08
WO2002067893A3 (en)	2003-01-16
HUP0302847A2 (hu)	2003-12-29
CA2439366A1 (en)	2002-09-06
ATE307571T1 (de)	2005-11-15
DE60206889T2 (de)	2006-07-27
EP1368001B1 (en)	2005-10-26
JP2004143185A (ja)	2004-05-20
NZ527532A (en)	2004-12-24
CN1503662A (zh)	2004-06-09

Legal Events

Date	Code	Title	Description
2009-06-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
HUP0302847A3 (en)	2005-05-30	Pharmaceutical formulation comprising bicalutamide
IL156716A0 (en)	2004-01-04	Pharmaceutical formulation
GB0319041D0 (en)	2003-09-17	Pharmaceutical Formulations
GB0118689D0 (en)	2001-09-19	Pharmaceutical formulation
GB0111597D0 (en)	2001-07-04	Pharmaceutical compositions
PL366432A1 (pl)	2005-01-24	Preparat farmaceutyczny
GB0121715D0 (en)	2001-10-31	Pharmaceutical formulations
GB2380129B (en)	2004-08-11	Pharmaceutical formulations
IL161902A0 (en)	2005-11-20	Pharmaceutical formulation comprising bicalutamide
GB0120701D0 (en)	2001-10-17	Pharmaceutical formulations
GB0103638D0 (en)	2001-03-28	Pharmaceutical formulations
IL161306A0 (en)	2004-09-27	Pharmaceutical formulation comprising (r)-bicalutamide
GB0105560D0 (en)	2001-04-25	Pharmaceutical formulations
GB0104752D0 (en)	2001-04-18	Pharmaceutical compositions
GB0125492D0 (en)	2001-12-12	Formulation
GB2382302B (en)	2006-08-02	Pharmaceutical compositions
ZA200306383B (en)	2004-11-15	Pharmaceutical formulation comprising bicalutamide.
GB0124455D0 (en)	2001-12-05	Pharmaceutical formulations
GB2396812B (en)	2005-11-02	Formulation
GB2375048B (en)	2003-11-19	Formulation
GB0116619D0 (en)	2001-08-29	Formulation
GB0128138D0 (en)	2002-01-16	Pharmaceutical use
HK1066729A (en)	2005-04-01	Pharmaceutical formulation comprising bicalutamide
HK1059743A (en)	2004-07-16	Pharmaceutical formulation comprising bicalutamide
GB0112497D0 (en)	2001-07-11	Formulation